1. Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

2. MSBase and TOP: Switch to Fingolimod or Natalizumab vs BRACE Therapies

3. PREFERMS: Patients Switching to Fingolimod From IFN-β or GA

4. Efficacy of DMF by Prior DMT Use

5. PML Risk/Year Stratified by Index Value

6. Fingolimod: Relapse Rates in Patients Who Discontinue Natalizumab

7. Risk for PML With MS Therapies

8. Shorter Natalizumab Washout Periods Are Associated With Less Disease Activity

9. The Impact of Switching Time From Natalizumab to Fingolimod on Imaging and Clinical Effectiveness Outcomes

10. Fingolimod 0.5 mg and Major Infections

11. Abbreviations

12. Abbreviations (cont)